The emerging role of CXC chemokines in epithelial ovarian cancer

Reproduction

Volumn 144, Issue 3, 2012, Pages 303-317

  Rainczuk, Adam ^a   Rao, Jyothsna ^a   Gathercole, Jessica ^a   Stephens, Andrew N ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CXCL16 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 8; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; CANCER GROWTH; CANCER SURVIVAL; ENDOMETRIUM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; OVARY CARCINOMA; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOKINES, CXC; FEMALE; HUMANS; INFLAMMATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 84865198596     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-12-0153     Document Type: Review

References (133)

1. Agarwal A, Covic L, Sevigny LM, Kaneider NC, Lazarides K, Azabdaftari G, Sharifi S & Kuliopulos A 2008 Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Molecular Cancer Therapeutics 7 2746-2757. (doi:10.1158/1535-7163.MCT-08-0177)
2. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L & Kuliopulos A 2010 Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Research 70 5880-5890. (doi:10.1158/0008-5472.CAN-09-4341)
3. Aitokallio-Tallberg AM, Viinikka LU & Ylikorkala RO 1988 Increased synthesis of prostacyclin and thromboxane in human ovarian malignancy. Cancer Research 48 2396-2398.
4. Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y & Hirohashi S 2009 Prognostic significance of CXCL12 expression in patients with colorectal carcinoma. American Journal of Clinical Pathology 132 202-210 (quiz 307). (doi:10.1309/AJCPK35VZJEWCUTL)
5. Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, Flak MB, McNeish IA, Deen S, Brenton JD et al. 2012 Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene [in press]. (doi:10.1038/onc.2011.653)
6. Arnogiannaki N, Grigoriadis C, Zygouris D, Terzakis E, Sebastiadou M &Tserkezoglou A 2011 Proliferative Brenner tumor of the ovary. Clinicopathological study of two cases and review of the literature. European Journal of Gynaecological Oncology 32 576-578.
7. Auersperg N, Edelson MI, Mok SC, Johnson SW & Hamilton TC 1998 The biology of ovarian cancer. Seminars in Oncology 25 281-304. (Pubitemid 28272603)
8. Balkwill F 2004 Cancer and the chemokine network. Nature Reviews. Cancer 4 540-550. (doi:10.1038/nrc1388)
9. Balkwill FR 2012 The chemokine system and cancer. Journal of Pathology 226 148-157. (doi:10.1002/path.3029)
10. Barbieri F, Bajetto A & Florio T 2010 Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. Journal of Oncology 2010 426956. (doi:10.1155/2010/ 426956)
11. Boimel PJ, Smirnova T, Zhou ZN, Wyckoff J, Park HI, Coniglio SJ, Patel P, Qian BZ, Stanley ER, Bresnick AR et al. 2012 Contribution of CXCL12 secretion to invasion of breast cancer cells. Breast Cancer Research 14 R23. (doi:10.1186/bcr3108)
12. Bolitho C, Hahn MA, Baxter RC & Marsh DJ 2010 The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor. Endocrine-Related Cancer 17 929-940. (doi:10.1677/ERC-10-0107)
13. Callesen AK, Madsen JS, Iachina M, Vach W, Kruse TA, Jensen ON &Mogensen O 2010 Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor. Cancer Biomarkers 6 73-82. (doi:10.3233/CBM-2009-0120)
14. Campanella GS, Colvin RA & Luster AD 2010 CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS ONE 5 e12700. (doi:10.1371/journal.pone.0012700)
15. Cannon MJ, Goyne H, Stone PJ & Chiriva-Internati M 2011 Dendritic cell vaccination against ovarian cancer - tipping the Treg/TH17 balance to therapeutic advantage? Expert Opinion on Biological Therapy 11 441-445. (doi:10.1517/14712598.2011.554812)
16. CGARN 2011 Integrated genomic analyses of ovarian carcinoma. Nature 474 609-615. (doi:10.1038/nature10166)
17. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, Cremer I, Fridman WH, Sautes-Fridman C & Dieu-Nosjean MC 2011 Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Research 71 6391-6399. (doi:10.1158/0008-5472.CAN-11-0952)
18. Charo IF & Ransohoff RM 2006 The many roles of chemokines and chemokine receptors in inflammation. New England Journal of Medicine 354 610-621. (doi:10.1056/NEJMra052723)
19. Cho KR 2009 Ovarian cancer update: lessons from morphology, molecules, and mice. Archives of Pathology & Laboratory Medicine 133 1775-1781. (doi:10.1043/1543-2165-133.11.1775)
20. Cho KR & Shih Ie M 2009 Ovarian cancer. Annual Review of Pathology 4 287-313. (doi:10.1146/annurev.pathol.4.110807.092246)
21. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG et al. 2009 Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology 22 393-402. (doi:10.1038/modpathol.2008.191)
22. Clark-Lewis I, Mattioli I, Gong JH & Loetscher P 2003 Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. Journal of Biological Chemistry 278 289-295. (doi:10.1074/jbc. M209470200)
23. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, Lokshin AE, Idahl A, Ohlson N, Hallmans G et al. 2011 Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention 20 799-810. (doi:10.1158/1055-9965.EPI-10-1180)
24. Coffelt SB & Scandurro AB 2008 Tumors sound the alarmin(s). Cancer Research 68 6482-6485. (doi:10.1158/0008-5472.CAN-08-0044)
25. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A & Lee Y 2007 Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research 5 35-44. (doi:10.3121/cmr.2007.702)
26. Cuenca RE, Azizkhan RG & Haskill S 1992 Characterization of GROα, β and γ expression in human colonic tumours: potential significance of cytokine involvement. Surgical Oncology 1 323-329. (doi:10.1016/0960-7404(92)90094-2)
27. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10 942-949. (doi:10.1038/nm1093)
28. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, Singh SP, Bedolla RB, Peled A, Troyer DA et al. 2009 The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS ONE 4 e6695. (doi:10.1371/journal.pone.0006695)
29. De Larco JE, Wuertz BR & Furcht LT 2004 The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clinical Cancer Research 10 4895-4900. (doi:10.1158/1078-0432. CCR-03-0760)
30. Demopoulos RI, Aronov R & Mesia A 2001 Clues to the pathogenesis of fallopian tube carcinoma: a morphological and immunohistochemical case control study. International Journal of Gynecological Pathology 20 128-132. (doi:10.1097/00004347-200104000-00003)
31. Deng L, Chen N, Li Y, Zheng H & Lei Q 2010 CXCR6/CXCL16 functions as a regulator in metastasis and progression of cancer. Biochimica et Biophysica Acta 1806 42-49.
32. Eck M, Schmausser B, Scheller K, Brandlein S & Muller-Hermelink HK 2003 Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clinical and Experimental Immunology 134 508-515. (doi:10.1111/j.1365-2249.2003.02305.x)
33. Erreni M, Bianchi P, Laghi L, Mirolo M, Fabbri M, Locati M, Mantovani A &Allavena P 2009 Expression of chemokines and chemokine receptors in human colon cancer. Methods in Enzymology 460 105-121. (doi:full-text)
34. Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L et al. 2010 CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Research 30 4791-4798.
35. Fernandez EJ & Lolis E 2002 Structure, function, and inhibition of chemokines. Annual Review of Pharmacology and Toxicology 42 469-499. (doi:10.1146/annurev.pharmtox.42.091901.115838)
36. Fleming JS, Beaugie CR, Haviv I, Chenevix-Trench G & Tan OL 2006 Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses. Molecular and Cellular Endocrinology 247 4-21. (doi:10.1016/j.mce.2005.09.014)
37. Frick VO, Rubie C, Wagner M, Graeber S, Grimm H, Kopp B, Rau BM & Schilling MK 2008 Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 8 488-497. (doi:10.1159/000151776)
38. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, Ishiwata I, Nagai Y, Shozu M & Kimura S 2007 Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Human Pathology 38 1676-1687. (doi:10.1016/j. humpath.2007.03.023)
39. Furuya M, Yoneyama T, Miyagi E, Tanaka R, Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y & Aoki I 2011 Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Gynecologic Oncology 122 648-655. (doi:10.1016/j.ygyno.2011. 05.034)
40. Gacci M, Serni S, Lapini A, Vittori G, Alessandrini M, Nesi G, Palli D &Carini M 2009 CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. Journal of Urology 181 843-848. (doi:10.1016/j.juro. 2008.10.063)
41. Gelmini S, Mangoni M, Castiglione F, Beltrami C, Pieralli A, Andersson KL, Fambrini M, Taddei GL, Serio M & Orlando C 2009 The CXCR4/CXCL12 axis in endometrial cancer. Clinical & Experimental Metastasis 26 261-268. (doi:10.1007/s10585-009-9240-4)
42. Gijsbers K, Gouwy M, Struyf S, Wuyts A, Proost P, Opdenakker G, Penninckx F, Ectors N, Geboes K & Van Damme J 2005 GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Experimental Cell Research 303 331-342. (doi:10.1016/j.yexcr.2004.09.027)
43. Gilks CB, Ionescu DN, Kalloger SE, Kobel M, Irving J, Clarke B, Santos J, Le N, Moravan V & Swenerton K 2008 Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology 39 1239-1251. (doi:10.1016/j.humpath.2008.01.003)
44. Giuliani N, Bonomini S, Romagnani P, Lazzaretti M, Morandi F, Colla S, Tagliaferri S, Lasagni L, Annunziato F, Crugnola M et al. 2006 CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival. Haematologica 91 1489-1497. (Pubitemid 44736115)
45. Gottlieb AB, Luster AD, Posnett DN & Carter DM 1988 Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. Journal of Experimental Medicine 168 941-948. (doi:10.1084/jem.168.3.941)
46. Goyne H, Stone PJ & Cannon MJ 2011 Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer. Immunotherapy 3 805-807. (doi:10.2217/imt.11.71)
47. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M & Ward B 1997 Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. International Journal of Cancer 71 948-951. (doi:10.1002/(SICI)1097-0215(19970611)71:6〈948::AID-IJC6〉3.0. CO;2-Y)
48. Griffioen AW & Molema G 2000 Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacological Reviews 52 237-268. (Pubitemid 30368433)
49. Groom JR & Luster AD 2011 CXCR3 in T cell function. Experimental Cell Research 317 620-631. (doi:10.1016/j.yexcr.2010.12.017)
50. Gutwein P, Schramme A, Sinke N, Abdel-Bakky MS, Voss B, Obermuller N, Doberstein K, Koziolek M, Fritzsche F, Johannsen M et al. 2009 Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. European Journal of Cancer 45 478-489. (doi:10.1016/j.ejca. 2008.10.023)
51. Ha HK, Lee W, Park HJ, Lee SD, Lee JZ & Chung MK 2011 Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer. Molecular Medicine Reports 4 419-424. (doi:10.3892/mmr.2011.446)
52. Hassan S, Ferrario C, Saragovi U, Quenneville L, Gaboury L, Baccarelli A, Salvucci O & Basik M 2009 The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. American Journal of Pathology 175 66-73. (doi:10.2353/ajpath.2009.080948)
53. Hojo S, Koizumi K, Tsuneyama K, Arita Y, Cui Z, Shinohara K, Minami T, Hashimoto I, Nakayama T, Sakurai H et al. 2007 High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Research 67 4725-4731. (doi:10.1158/0008-5472.CAN-06-3424)
54. van der Horst PH, Wang Y, Vandenput I, Kuhne LC, Ewing PC, van Ijcken WF, van der Zee M, Amant F, Burger CW & Blok LJ 2012 Progesterone inhibits epithelial-to-mesenchymal transition in endometrial cancer. PLoS ONE 7 e30840. (doi:10.1371/journal.pone.0030840)
55. Hwang WT, Adams SF, Tahirovic E, Hagemann IS & Coukos G 2012 Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic Oncology 124 192-198. (doi:10.1016/j.ygyno.2011.09. 039)
56. Jiang YP, Wu XH, Shi B, Wu WX & Yin GR 2006 Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecologic Oncology 103 226-233. (doi:10.1016/j.ygyno.2006.02.036)
57. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A & Kikkawa F 2008 Involvement of SDF-1a/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. International Journal of Cancer 122 91-99. (doi:10.1002/ijc.23083)
58. Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T &Nakano H 2003 Histological classification of ovarian cancer. Medical Electron Microscopy 36 9-17. (doi:10.1007/s007950300002)
59. Karstrom-Encrantz L, Runesson E, Bostrom EK & Brannstrom M 1998 Selective presence of the chemokine growth-regulated oncogene α (GROα) in the human follicle and secretion from cultured granulosalutein cells at ovulation. Molecular Human Reproduction 4 1077-1083. (doi:10.1093/molehr/4.11.1077)
60. Keeley EC, Mehrad B & Strieter RM 2008 Chemokines as mediators of neovascularization. Arteriosclerosis, Thrombosis, and Vascular Biology 28 1928-1936. (doi:10.1161/ATVBAHA.108.162925)
61. Kelley TW & Parker CJ 2010 CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies. Frontiers in Bioscience 2 980-992. (doi:10.2741/S114)
62. Kiefer F & Siekmann AF 2011 The role of chemokines and their receptors in angiogenesis. Cellular and Molecular Life Sciences 68 2811-2830. (doi:10.1007/s00018-011-0677-7)
63. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM & Matzuk MM 2012 High-grade serous ovarian cancer arises from fallopian tube in a mouse model. PNAS 109 3921-3926. (doi:10.1073/pnas.1117135109)
64. Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K & Sulowska Z 2008 Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scandinavian Journal of Immunology 68 328-336. (doi:10.1111/j.1365-3083.2008.02139.x)
65. Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A et al. 2008 Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medicine 5 e232. (doi:10.1371/journal.pmed.0050232)
66. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V et al. 2005 CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research 65 465-472.
67. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al. 2009 Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114 1141-1149. (doi:10.1182/blood-2009-03-208249)
68. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM et al. 2012 A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Research 72 66-75. (doi:10.1158/0008-5472.CAN-11-2178)
69. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E et al. 2003 An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. Journal of Experimental Medicine 197 1537-1549. (doi:10.1084/jem. 20021897)
70. Li A, Dubey S, Varney ML, Dave BJ & Singh RK 2003 IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Journal of Immunology 170 3369-3376. (Pubitemid 36302216)
71. Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M et al. 2011 Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. American Journal of Pathology 178 1340-1349. (doi:10.1016/j.ajpath.2010.11.058)
72. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM & Gorelik E 2006 Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecologic Oncology 102 244-251. (doi:10.1016/j.ygyno.2005.12.011)
73. Ludwig A, Schulte A, Schnack C, Hundhausen C, Reiss K, Brodway N, Held-Feindt J & Mentlein R 2005 Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. Journal of Neurochemistry 93 1293-1303. (doi:10.1111/j.1471-4159.2005.03123.x)
74. Maccio A & Madeddu C 2012 Inflammation and ovarian cancer. Cytokine 58 133-147. (doi:10.1016/j.cyto.2012.01.015)
75. Machelon V, Gaudin F, Camilleri-Broet S, Nasreddine S, Bouchet-Delbos L, Pujade-Lauraine E, Alexandre J, Gladieff L, Arenzana-Seisdedos F, Emilie D et al. 2011 CXCL12 expression by healthy and malignant ovarian epithelial cells. BMC Cancer 11 97. (doi:10.1186/1471-2407-11-97)
76. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P & Bonecchi R 2010 The chemokine system in cancer biology and therapy. Cytokine &Growth Factor Reviews 21 27-39. (doi:10.1016/j.cytogfr.2009.11.007)
77. Masoumi Moghaddam S, Amini A, Morris DL & Pourgholami MH 2012 Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer and Metastasis Reviews 31 143-162. (doi:10.1007/s10555-011-9337-5)
78. Matsubara J, Honda K, Ono M, Tanaka Y, Kobayashi M, Jung G, Yanagisawa K, Sakuma T, Nakamori S, Sata N et al. 2011 Reduced plasma level of CXC chemokine ligand 7 in patients with pancreatic cancer. Cancer Epidemiology, Biomarkers & Prevention 20 160-171. (doi:10.1158/1055-9965.EPI-10-0397)
79. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, Garber JE, Cramer DW & Crum CP 2006 The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. American Journal of Surgical Pathology 30 230-236. (doi:10.1097/01.pas.0000180854.28831.77)
80. Merritt MA & Cramer DW 2011 Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomarkers 9 287-305. (doi:10.3233/CBM-2011-0167)
81. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE & Haites NE 1993 p53 mutation is a common genetic event in ovarian carcinoma. Cancer Research 53 2128-2132. (Pubitemid 23145738)
82. Miyanishi N, Suzuki Y, Simizu S, Kuwabara Y, Banno K & Umezawa K 2010 Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. Biochemical and Biophysical Research Communications 403 154-159. (doi:10.1016/j.bbrc.2010.11.007)
83. Moore SW & Enterline HT 1975 Significance of proliferative epithelial lesions of the uterine tube. Obstetrics and Gynecology 45 385-390.
84. Mortier A, Loos T, Gouwy M, Ronsse I, Van Damme J & Proost P 2010 Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine deiminases (PAD) differently affects its biological activity. Journal of Biological Chemistry 285 29750-29759. (doi:10.1074/jbc. M110.119388)
85. Mortier A, Gouwy M, Van Damme J & Proost P 2011 Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Experimental Cell Research 317 642-654. (doi:10.1016/j.yexcr.2010.11.016)
86. Mukaida N & Baba T 2012 Chemokines in tumor development and progression. Experimental Cell Research 318 95-102. (doi:10.1016/j.yexcr.2011. 10.012)
87. Munn DH 2009 Th17 cells in ovarian cancer. Blood 114 1134-1135. (doi:10.1182/blood-2009-06-224246)
88. Murdoch WJ & McDonnel AC 2002 Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 123 743-750. (doi:10.1530/rep.0. 1230743)
89. Murdoch WJ, Murphy CJ, Van Kirk EA & Shen Y 2010 Mechanisms and pathobiology of ovulation. Society of Reproduction and Fertility. Supplement 67 189-201.
90. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O & Sasaki I 2005 Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. International Journal of Cancer 116 949-956. (doi:10.1002/ijc.21135)
91. Naldini A, Morena E, Belotti D, Carraro F, Allavena P & Giavazzi R 2011 Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thrombosis and Haemostasis 106 705-711. (doi:10.1160/TH11-05-0311)
92. Ness RB & Cottreau C 1999 Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute 91 1459-1467. (doi:10.1093/jnci/91.17.1459)
93. Ness RB & Modugno F 2006 Endometriosis as a model for inflammation-hormone interactions in ovarian and breast cancers. European Journal of Cancer 42 691-703. (doi:10.1016/j.ejca.2006.01.009)
94. Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M & Schlesselman JJ 2000 Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 11 111-117. (doi:10.1097/00001648-200003000-00006)
95. Ohtani H, Jin Z, Takegawa S, Nakayama T & Yoshie O 2009 Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+T cells in lymphocyte-rich gastric carcinoma. Journal of Pathology 217 21-31. (doi:10.1002/path.2448)
96. Ray P, Lewin SA, Mihalko LA, Schmidt BT, Luker KE & Luker GD 2011 Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia 13 1152-1161.
97. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D et al. 2011 CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Research 71 5522-5534. (doi:10.1158/0008-5472.CAN-10-3143)
98. Roett MA & Evans P 2009 Ovarian cancer: an overview. American Family Physician/GP 80 609-616.
99. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L et al. 2001 Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. Journal of Clinical Investigation 107 53-63. (doi:10.1172/JCI9775)
100. Romagnani P, Lasagni L, Annunziato F, Serio M & Romagnani S 2004 CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends in Immunology 25 201-209. (doi:10.1016/j.it.2004.02.006)
101. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. PNAS 102 18538-18543. (doi:10.1073/pnas.0509182102)
102. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P et al. 2002 Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. Journal of Biological Chemistry 277 24584-24593. (doi:10.1074/jbc. M112275200)
103. Scotton CJ, Wilson JL, Milliken D, Stamp G & Balkwill FR 2001 Epithelial cancer cell migration: a role for chemokine receptors? Cancer Research 61 4961-4965. (Pubitemid 32681518)
104. Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G & Balkwill FR 2002 Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Research 62 5930-5938. (Pubitemid 35204756)
105. Seidman JD, Sherman ME, Bell KA, Katabuchi H, O'Leary TJ & Kurman RJ 2002 Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection? International Journal of Gynecological Pathology 21 101-107. (doi:10.1097/00004347-200204000-00001)
106. Sheng XJ, Zhou YQ, Song QY, Zhou DM & Liu QC 2012 Loss of breast cancer metastasis suppressor 1 promotes ovarian cancer cell metastasis by increasing chemokine receptor 4 expression. Oncology Reports 27 1011-1018. (doi:10.3892/or.2011.1596)
107. Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS et al. 2012 Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis. Oncogene 31 706-715. (doi:10.1038/onc.2011.275)
108. Son DS, Parl AK, Rice VM & Khabele D 2007 Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and proinflammatory chemokine networks in mouse and human ovarian epithelial cancer cells. Cancer Biology and Therapy 6 1302-1312. (doi:10.4161/cbt.6.8.4506)
109. Spinetti G, Camarda G, Bernardini G, Romano Di Peppe S, Capogrossi MC & Napolitano M 2001 The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochemical and Biophysical Research Communications 289 19-24. (doi:10.1006/bbrc.2001.5924)
110. Strandell A, Thorburn J & Wallin A 2004 The presence of cytokines and growth factors in hydrosalpingeal fluid. Journal of Assisted Reproduction and Genetics 21 241-247. (doi:10.1023/B:JARG.0000042009.93520.15)
111. Strieter RM, Belperio JA, Phillips RJ & Keane MP 2004 CXC chemokines in angiogenesis of cancer. Seminars in Cancer Biology 14 195-200. (doi:10.1016/j.semcancer.2003.10.006)
112. Strieter RM, Burdick MD, Mestas J, Gomperts B, Keane MP & Belperio JA 2006 Cancer CXC chemokine networks and tumour angiogenesis. European Journal of Cancer 42 768-778. (doi:10.1016/j.ejca.2006.01.006)
113. Struyf S, Burdick MD, Peeters E, Van den Broeck K, Dillen C, Proost P, Van Damme J & Strieter RM 2007 Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Research 67 5940-5948. (doi:10.1158/0008-5472.CAN-06-4682)
114. Subbaramaiah K, Telang N, Bansal MB, Weksler BB & Dannenberg AJ 1997 Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells. Annals of the New York Academy of Sciences 833 179-185. (doi:10.1111/j.1749-6632.1997.tb48606.x)
115. Tomsova M, Melichar B, Sedlakova I & Steiner I 2008 Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecologic Oncology 108 415-420. (doi:10.1016/j.ygyno.2007.10.016)
116. Vang R, Shih Ie M & Kurman RJ 2009 Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Advances in Anatomic Pathology 16 267-282. (doi:10.1097/PAP.0b013e3181b4fffa)
117. Wang Y, Yang J, Gao Y, Du Y, Bao L, Niu W & Yao Z 2005 Regulatory effect of e2, IL-6 and IL-8 on the growth of epithelial ovarian cancer cells. Cellular & Molecular Immunology 2 365-372.
118. Wang Q, Li D, Zhang W, Tang B, Li QQ & Li L 2011 Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses. International Journal of Biological Markers 26 262-273. (doi:10.5301/JBM.2011. 8616)
119. Whitworth JM & Alvarez RD 2011 Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opinion on Biological Therapy 11 751-762. (doi:10.1517/14712598.2011.566854)
120. Wilke CM, Bishop K, Fox D & Zou W 2011 Deciphering the role of Th17 cells in human disease. Trends in Immunology 32 603-611. (doi:10.1016/j.it.2011. 08.003)
121. Wislez M, Philippe C, Antoine M, Rabbe N, Moreau J, Bellocq A, Mayaud C, Milleron B, Soler P & Cadranel J 2004 Upregulation of bronchioloalveolar carcinoma-derived C-X-C chemokines by tumor infiltrating inflammatory cells. Inflammation Research 53 4-12. (doi:10.1007/s00011-003-1215-3)
122. Wong KH, Negishi H & Adashi EY 2002 Expression, hormonal regulation, and cyclic variation of chemokines in the rat ovary: key determinants of the intraovarian residence of representatives of the white blood cell series. Endocrinology 143 784-791. (doi:10.1210/en.143.3.784)
123. Wu QD, Wang JH, Condron C, Bouchier-Hayes D & Redmond HP 2001 Human neutrophils facilitate tumor cell transendothelial migration. American Journal of Physiology. Cell Physiology 280 C814-C822.
124. 2-terminal heterogeneity. Functional comparison of different natural isoforms. European Journal of Biochemistry 260 421-429. (doi:10.1046/j.1432-1327.1999.00166.x)
125. Yang G, Rosen DG, Zhang Z, Bast RC Jr, Mills GB, Colacino JA, Mercado-Uribe I & Liu J 2006 The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. PNAS 103 16472-16477. (doi:10.1073/pnas.0605752103)
126. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, Kuliopulos A &Covic L 2009 Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Research 69 6223-6231. (doi:10.1158/0008-5472. CAN-09-0187)
127. Yigit R, Massuger LF, Zusterzeel PL, Pots J, Figdor CG & Torensma R 2011 Cytokine profiles in cyst fluids from ovarian tumors reflect immunosuppressive state of the tumor. International Journal of Gynecological Cancer 21 1241-1247. (doi:10.1097/IGC.0b013e3182289ab1)
128. Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu HZ, Li WM, Liu HT & Wang YX 2011 Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. Oncology Reports 26 671-679. (doi:10.3892/or.2011.1334)
129. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD & Fidler IJ 1998 Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. Journal of the National Cancer Institute 90 447-454. (doi:10.1093/jnci/90.6.447)
130. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al. 2003 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348 203-213. (doi:10.1056/NEJMoa020177)
131. Zhou C, Borillo J, Wu J, Torres L & Lou YH 2004 Ovarian expression of chemokines and their receptors. Journal of Reproductive Immunology 63 1-9. (doi:10.1016/j.jri.2004.03.002)
132. Zlotnik A, Burkhardt AM & Homey B 2011 Homeostatic chemokine receptors and organ-specific metastasis. Nature Reviews. Immunology 11 597-606. (doi:10.1038/nri3049)
133. Zou W & Restifo NP 2010 T(H)17 cells in tumour immunity and immunotherapy. Nature Reviews. Immunology 10 248-256. (doi:10.1038/nri2742)